Compare GLSI & KINS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLSI | KINS |
|---|---|---|
| Founded | 2006 | 1886 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 254.7M | 284.5M |
| IPO Year | 2020 | 2013 |
| Metric | GLSI | KINS |
|---|---|---|
| Price | $14.59 | $18.66 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $57.00 | N/A |
| AVG Volume (30 Days) | ★ 131.4K | 71.4K |
| Earning Date | 11-13-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 1.29% |
| EPS Growth | N/A | ★ 94.59 |
| EPS | N/A | ★ 0.66 |
| Revenue | N/A | ★ $214,867,301.00 |
| Revenue This Year | N/A | $18.83 |
| Revenue Next Year | N/A | $15.85 |
| P/E Ratio | ★ N/A | $28.15 |
| Revenue Growth | N/A | ★ 38.50 |
| 52 Week Low | $7.78 | $13.83 |
| 52 Week High | $34.10 | $20.90 |
| Indicator | GLSI | KINS |
|---|---|---|
| Relative Strength Index (RSI) | 40.57 | 49.95 |
| Support Level | $14.57 | $18.68 |
| Resistance Level | $19.97 | $19.31 |
| Average True Range (ATR) | 1.46 | 0.46 |
| MACD | -0.27 | 0.07 |
| Stochastic Oscillator | 13.81 | 75.41 |
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.
Kingstone Companies Inc offers property and casualty insurance products through its subsidiary engaged in writing business through retail and wholesale agents and brokers. Its products include Personal lines, Livery physical damage, and Others. It operates in single segment, property and casualty insurance. It derives substantially all of its revenue from KICO, including revenues from earned premiums, ceding commissions from quota share reinsurance, net investment income generated from its investment portfolio, and net realized gains and losses on investment securities.